Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
Status:
Not yet recruiting
Trial end date:
2025-05-27
Target enrollment:
Participant gender:
Summary
This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled
study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240
mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically
confirmed diagnosis of IgE-mediated peanut allergy.